(Information sent by the signatory company)

DIJON, France and LEIDEN, Netherlands, January 23, 2024 /PRNewswire/ — Oncodesign Services (ODS), a leading Contract Research Organization specializing in drug discovery and preclinical services, announces its international expansion through the acquisition of ZoBio, a Dutch CRO specialized in small molecule drug discovery from biophysics.

This acquisition allows ODS to strengthen and expand its knowledge and capabilities in the field of small molecule discovery into a fully integrated offering to support its clients’ innovative programs, from target validation to candidate selection.

ODS is especially recognized for its expertise in the preclinical evaluation of experimental therapies in major disease areas such as oncology and immunoinflammation, as well as its expertise in medicinal chemistry, computational chemistry, DMPK, pharmacoimaging, and molecular radiotherapy. The company has managed to develop several drug candidates that have reached the clinical development phase together with its partner clients.

Founded more than 19 years ago, ZoBio has achieved an excellent scientific reputation and innovation in the field of drug discovery from biophysics. With a best-in-class platform in protein sciences, biophysical and functional assays, structural biology, and a unique and well-diversified small molecule compound library, ZoBio has helped its customers bring multiple compounds to the clinic.

With this transaction, ODS and ZoBio together represent almost 280 employees spread between Dijon and Les Ulis in France, Leiden in the Netherlands and with subsidiaries in Canada and the United States. This agreement lays the foundation for ODS’s ambition to become a European leader in Drug Discovery, offering fully integrated drug discovery services and solutions, placing quality, scientific creativity, operational excellence and transparency in customer relationships. at the center of its strategy and investing in innovative technologies.

Dr. Fabrice Viviani, CEO of ODS: “I am deeply grateful to my executive team with Gilles Cadiou, Sébastien Simon, Stephanie Belattar and our investors Jean-François Felix and Maxence de Vienne, from Elyan Partners, who have been instrumental in making this operation be a real success.

We are very pleased to welcome ZoBio to the Group and thus strengthen our offering of preclinical small molecule drug discovery services, from gene to human genome, with cutting-edge competencies and technologies.

Oncodesign Services and ZoBio are highly complementary, and we are extremely pleased that Gregg Siegal, Rob Heetebrij and Jan Schultz have decided to continue the adventure and commitment with us to identify novel preclinical candidates for our clients in major disease areas, and also benefit from the numerous future commercial and operational synergies.”

Dr. Gregg Siegal, CEO of ZoBio: “We are truly excited about the opportunity to combine our best-in-class fragment-based drug discovery platform with the expertise of Oncodesign Services. We have explored many ways to strategically expand our capabilities.” to cover a larger part of the drug discovery process and ODS was by far the best fit. We now look forward to integrating with the Fabrice team and bringing the best of both companies to our clients.”

About Oncodesign Services (ODS):

Oncodesign Services (ODS) is a leading CRO specializing in drug discovery and preclinical services. It contributes to the development of innovative therapies in oncology, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, DMPK, pharmacoimaging, bioanalysis and in vivo/in vitro pharmacology. Oncodesign Services has 230 employees in France and Canada.

More information: www.oncodesign-services.com

About ZoBio:

ZoBio has built a class-leading platform that provides a complete solution for fragment-based drug discovery. Our capabilities include: protein production, biophysical and functional assays, structural biology (crystallography, NMR and cryoEM), and fragment-focused medicinal chemistry. Our 46-person team brings dedication and expertise to help solve your biggest drug discovery challenges.

More information: http://www.zobio.com

Contact: contact@oncodesign-services.com

Logo – https://mma.prnewswire.com/media/2324606…

View original content: https://www.prnewswire.com/news-releases/oncodesign-services-una-organizacion-de-investigacion-por-contrato-cro-por-sus-siglas-en-ingles-europea-lider-en-el-descubrimiento-preclinico-de-farmacos-adquiere-zobio-una-cro-especializada-en-el-descubrimiento-de-farmacos-d-302041799.html